Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reissue Patent
2011-05-17
2011-05-17
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C540S455000, C540S460000
Reissue Patent
active
RE042375
ABSTRACT:
The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
REFERENCES:
patent: 6329379 (2001-12-01), Llinas-Brunet et al.
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 2002/0037998 (2002-03-01), Llinas-Brunet et al.
patent: WO-00/09543 (2000-02-01), None
patent: WO-00/59929 (2000-10-01), None
patent: WO-2003/053349 (2003-07-01), None
patent: WO-2004/072243 (2004-08-01), None
M. Llinás-Burnet et al., “Peptide-Based Inhibitors of the Hepatitis C Virus Serine Protease,” Bioorganic & Medicinal Chemistry Letters 8, (1998), pp. 1713-1718.
A. Spatola, “Peptide Backbone Modifications: A Structure-Activity Analysis of Peptides Containing Amide Bond Surrogates, Conformational Constraints, and Rela,” Department of Chemistry, University of Louisville, Louisville Kentucky, pp. 267-357, XP 002032461.
Miao Zhenwei
Nakajima Suanne
Or Yat Sun
Porter Brian
Sun Ying
Elmore Patent Law Group P.C.
Elmore, Esq. Carolyn S.
Enanta Pharmaceuticals, Inc.
Harlan Edgar W.
Kifle Bruck
LandOfFree
Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2684575